You might be onto something if the app was being pitched at a hospital or GP setting in suburban Australia.
However a hospital, an X-ray & a full clinical diagnosis for common resp. conditions (which requires access to the full range of diagnostic tools) by a doctor is not currently available globally to/or deemed necessary by many countries for all patients. That's where remote clinics, nurse practitioners & Telehealth fits in.
RAP is initially taking ResApp (if fully validated & approved) to the European tele-health market which is much more evolved than it is Australia & on a steep growth curve. Beyond that (IMHO) there are broad applications for app inc. ED's, screening (pre-employment, airports) remote medicine and primary health care settings (home & community) just to name a few.
RAP Price at posting:
22.0¢ Sentiment: Buy Disclosure: Held